-
-
-
-
-
-
-
Genentech reports positive Phase III results for uveitic macular edema drug
-
-
-
-
-
-
-
FDA rejects Genentech's Columvi combination for lymphoma treatment
-
-
-
-
-
-
-
FDA Approves Genentech’s Susvimo as Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
-
-
-
-
-
-
-
Roche stock down 5% after disappointing drug trial data update
-
-
-
-
-
-
-
Roche Holding (ROG:SW) (RHHBY) PT Raised to CHF305 at Bernstein SocGen Group
-
-
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

